All trial summaries

Impact of cancer screening on metastasis: A prostate cancer case study

Jane Lange, Sebastiaan Remmers, Roman Gulati, Anna Bill-Axelson, Jan-Erik Johansson, Maciej Kwiatkowski, Anssi Auvinen, Jonas Hugosson, Jim C Hu, Monique J Roobol, Sigrid V Carlsson, Ruth Etzioni

J Med Screen . 2021

Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort study

Mats Steinholtz Ahlberg, Hans Garmo, Hans-Olov Adami, Ove Andrén, Jan-Erik Johansson, Gunnar Steineck, Lars Holmberg, Anna Bill-Axelson

Time depencence of outcomes in the SPCG-4 randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

Lars Holmberg, Hans Garmo, Sven-Olov Andersson, Ove Andrén, Eva Johansson, Kimmo Taari, Michael Häggman, Stig Nordling, Hans-Olov Adami, Anna Bill-Axelson

Eur Urol . 2025

Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)

Sven Löffeler, Helena Bertilsson, Christoph Müller, Kirsti Aas, Hege Sagstuen Haugnes, Bjørg Aksnessæther, Maiju Pesonen, Kristian Thon, Torgrim Tandstad, Teemu Murtola, Mads Hvid Poulsen, Tobias Nordstrøm, Maria Nyre Vigmostad, Fredrik Ottosson, Karin Holmsten, Ola Christiansen, Marit Slaaen, Erik Skaaheim Haug, Anne Holck Storås, Lars Asphaug, Antti Rannikko, Klaus Brasso, For the Scandinavian Prostate Cancer Group (SPCG) and the Norwegian Get-Randomized (GRand) Initiative

BJU International

Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort study

Mats Steinholtz Ahlberg , Hans Garmo , Hans-Olov Adami , Ove Andrén , Jan-Erik Johansson , Gunnar Steineck , Lars Holmberg , Anna Bill-Axelson

BMJ Open

Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)

Andreas Josefsson, Åsa Jellvert, Erik Holmberg, Klaus Brasso, Peter Meidahl Petersen, Sirpa Aaltomaa, Marjaana Luukkaa, Paul Verhagen, Ronald de Wit, Göran Ahlgren, Ove Andrén, Enrique Castellanos, Mihalj Seke, Anders Widmark, Jan-Erik Damber & the SPCG14-investigators

ACTA ONCOLOGICA 2023, VOL. 62, NO. 4, 372–380

Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study

MIIKKA LEHTONEN, JORMA SORMUNEN, MARIE HJÄLM-ERIKSSON, CAMILLA THELLENBERG-KARLSSON, TEPPO HUTTUNEN, CLAES GINMAN and PIRKKO-LIISA KELLOKUMPU-LEHTINEN

ANTICANCER RESEARCH 42: 87-92 (2022)

Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study

Lehtonen M, Sormunen J, Hjälm-Eriksson M, Thellenberg-Karlsson C, Huttunen T, Ginman C, Kellokumpu-Lehtinen PL; Investigators of the Scandinavian Prostate Cancer Group Study No 13.

Anticancer Res. 2022 Jan

Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial

Bjørg Y Aksnessæther, Tor Åge Myklebust, Arne Solberg, Olbjørn H Klepp, Eva Skovlund, Solveig Roth Hoff, Sophie D Fosså, Anders Widmark, Jo-Åsmund Lund

J Radiat Oncol Biol Phys

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Lennart Åström, Lars Franzen, Ann-Sofie Fransson, Markku J Leskinen, Mihalj Zeke, Teppo Huttunen, Claes Ginman, Investigators of the Scandinavian Prostate Cancer Study No. 13

Eur Urol